Response to Letter to the Editor from Zandee and Links: “Metastatic Differentiated Thyroid Cancer Survival Is Unaffected by Mode of Preparation for 131I Administration”

Cristiane J. Gomes-Lima,1,2 Sanjita Chittimoju,3 Leen Wehbeh,3 Sunita Dia,3 Prathyusha Pagadala,3 Mohammad Al-Jundi,3 Sakshi Jhawar,4 Eshetu Tefera,5 Mihriye Mete,5,6 Joanna Klubo-Gwiezdzinska,6,7 Douglas Van Nostrand,1,7 and Kenneth D. Burman2,8

1MedStar Clinical Research Center, MedStar Health Research Institute (MHRI), Hyattsville, MD 20782-2031, USA
2Section of Endocrinology, MedStar Washington Hospital Center, Washington, DC 20010, USA
3Department of Internal Medicine, MedStar Washington Hospital Center, Washington, DC 20010, USA
4Department of Internal Medicine, Sinai Hospital of Baltimore, Research Volunteer, Baltimore, MD 21215, USA
5Department of Biostatistics, MedStar Health Research Institute (MHRI), Hyattsville, MD 20782-2031, USA
6Thyroid Tumors and Functional Thyroid Disorders Section, National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK), Bethesda, MD 20892, USA
7Nuclear Medicine Research, MedStar Washington Hospital Center, Washington, DC 20010, USA
8Division of Endocrinology, Department of Medicine, Georgetown University, Washington, DC 20057, USA

Correspondence: Cristiane J. Gomes-Lima, MD, PhD, SHIS 0123 • Conj. 4 • number 19, 71.660-040 Brasilia, DF, Brazil. Email: cjlima@gmail.com.

Abbreviations: DTC, differentiated thyroid cancer; RAI, radioiodine; rhTSH, recombinant human thyrotropin.

In our view, there is little doubt that use of recombinant human thyrotropin (rhTSH) has proved of significant benefit to patients with low- or intermediate-risk differentiated thyroid cancer (DTC). And in their communication regarding our study [1], Zandee and Links [2] present compelling arguments with which we fully agree on the importance and merits of also establishing that preparation by rhTSH for radioiodine (RAI) therapy of higher risk or metastatic DTC would be equally efficacious to preparation by thyroid hormone withdrawal. Insofar as our study did reach this conclusion, they express concern that we may have overstated that the results achieved by the 2 approaches were equivalent due to under-powering of the study. While our conclusions are supported by prior analyses as cited in our paper [3, 4], Zandee and Links [2] indicate that perhaps due to the multifarious nature of factors influencing thyroid cancer survival (in our subjects and presumably in general) that the failure to observe a statistically significant difference between the outcomes derived from the 2 approaches does not signify that they can be considered equivalent. While this inference is arguable, in our view it renders any conclusion inutile or ambiguous. Our cautionary conclusion was that the choice of preparation for RAI therapy would not “decisively affect outcome” because outcomes in the 2 groups of patients did not significantly differ statistically. We acknowledged multiple potential shortcomings of our study including the number of patients, duration of follow-up, selection bias, and retrospective design, and, as do Zandee and Links [2], look to the need for a perhaps international, carefully controlled larger study to more definitively resolve this question. Until such confirmatory data are available, we are comfortable continuing to offer the option of rhTSH preparation for RAI therapy to our patients with metastatic disease, with or without dosimetry, taking into account multiple factors known to influence either adverse or beneficial aspects of RAI therapy on an individual, personalized basis.

Disclosures
D.V.N.: speaker and consultant for Jubilant DraxImage. No competing financial interests exist for the remaining authors.

References
1. Gomes-Lima CJ, Chittimoju S, Wehbeh L, et al. Metastatic differentiated thyroid cancer survival is unaffected by mode of preparation for 131I administration. J Endocr Soc. 2022;6(5):bwac032.
2. Zandee WT, Links TP. Letter to the editor from Zandee and Links: “Metastatic differentiated thyroid cancer survival is unaffected by mode of preparation for 131I administration”. J Endocr Soc. 2023.
3. Tala H, Robbins R, Fagin JA, Larson SM, Turtle RM. Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. J Clin Endocrinol Metab. 2011;96(7):2105-2111.
4. Campopiano MC, Podestà D, Bianchi F, et al. No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH. Eur J Endocrinol. 2020;183(4):411-417.

Received: 8 December 2022. Editorial Decision: 9 January 2023. Corrected and Typeset: 9 February 2023
© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com